Psychopharmaceuticals for treatment of suicidal patients and for suicide prevention;Psychopharmaka zur Behandlung suizidaler Patienten und zur Suizidprävention

Nervenarzt

Volumn 87, Issue 5, 2016, Pages 483-487

  Haussmann R ^a   Bauer, M ^a   Lewitzka, U ^a   Muller Oerlinghausen B ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b ehemalige Institution Arzneimittelkommission der deutschen Ärzteschaft   (Germany)

Author keywords

Antidepressants; Clozapine; Lithium; Neuroleptics; Suicidality

Indexed keywords

CLOZAPINE; LITHIUM; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ARTICLE; EVIDENCE BASED PRACTICE; HUMAN; PSYCHOPHARMACOTHERAPY; SUICIDAL BEHAVIOR; PSYCHOLOGY; RECURRENT DISEASE; SUICIDAL IDEATION; SUICIDE; SUICIDE, ATTEMPTED;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; LITHIUM COMPOUNDS; PSYCHOTROPIC DRUGS; RECURRENCE; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; SUICIDAL IDEATION; SUICIDE; SUICIDE, ATTEMPTED;

EID: 84960129856     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-016-0088-y     Document Type: Article

References (46)

1. DGPPN et al (2009) S3-/Nationale Versorgungsleitlinie Unipolare Depression. Springer, Berlin
2. Wolfersdorf M, Etzersdorfer E (2011) Suizid und Suizidprävention. W. Kohlhammer, Stuttgart
3. Wolfersdorf M, Schneider B, Schmidtke A (2015) Suizidalität: ein psychiatrischer Notfall, Suizidprävention: eine psychiatrische Verpflichtung. Nervenarzt 86:1120–1129
4. Pfennig A, Berghöfer A, Bauer M (2005) Medikamentöse Behandlung der Suizidalität. Verhaltenstherapie 15:29–37
5. Schreiber J, Culpepper L (2015) Suicidal ideation and behaviour in adults, S 1–15. www.uptodate.com. Zugegriffen: 12.10.2015
6. Gründer G, Veselinovic T, Paulzen M (2014) Antidepressiva und Suizidalität. Nervenarzt 85:1108–1116
7. Hegerl U (2007) Antidepressiva und Suizidalität – Nutzen-Risiko-Abschätzung. Nervenarzt 78:7–14
8. Ärzteschaft, A.d.d. (2004) Mitteilung: SSRI und Suizidalität? Dtsch Arztebl 101(39):A-2642
9. Stübner S et al (2010) Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. J Clin Psychiatry 71(10):1293–1307
10. Bschor T (2015) Leserbrief – Antidepressiva verindern nicht Suizidversuche oder Suizide. Nervenarzt 86:1168–1170
11. Cipriani A et al (2005) Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162:1805–1819
12. Guzzetta F et al (2007) Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 68:380–383
13. Le Noury J et al (2015) Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 351:h4320 doi:10.1136/bmj.h4320
14. Coupland C et al (2015) Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. BMJ 350:h517 doi:10.1136/bmj.h517
15. Gibbons R et al (2012) Suicidal thoughts and behaviour with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 69:580–587
16. Stone M et al (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administraton. BMJ 339:b2880
17. Fergusson D et al (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ Open 330:396
18. Gunnel D, Saperia J, Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-anaylsis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 330:385
19. Hammad T, Laughren T, Racoosin J (2006) Suicide rates in short-term randomised controlled trials of newer antidepressants. J Clin Psychopharmacol 26:203–207
20. Khan A et al (2003) Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 160:790–792
21. Khan A et al (2001) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 4:113–118
22. Khan A, Warner H, Brown W (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Adminstration database. Arch Gen Psychiatry 57:311–317
23. Wassermann D et al (2012) The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry 27:129–141
24. Müller-Oerlinghausen B (2014) Suizidales Verhalten als unerwünschte Arzneimittelwirkung. Suizidprophylaxe 41(3):106–112
25. Mavrogiorgou P, Bründe M, Juckel G (2011) The management of psychiatric emergencies. Dtsch Arztebl Int 108:222–230
26. Cipriani A et al (2013) Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346:f3646
27. Ahrens B, Müller-Oerlinghausen B (2001) Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 34(4):132–136
28. Baldessarini R et al (2006) Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 8:625–639
29. Bschor T et al (2007) Twenty-five years of lithium augmentation. Nervenarzt 78:1237–1247
30. Crossley N, Bauer M (2007) Acceleration and augmentation of antdepressants with lithium for depressive disorders: two meta-analyses of randomized, plabo-controlled trials. J Clin Psychiatry 68:935–940
31. Lewitzka U, Bauer M (2014) What Role Does (Should) Lithium Play in Suicide Treatment/Prevention? Psychiatr Times 31:10–15
32. Müller-Oerlinghausen B et al (1992) The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 86:218–222
33. Felber W, Kyber A (1994) Suizide und Parasuizide während und außerhalb einer Lithiumprophylaxe. Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Georg Thieme Verlag, Stuttgart, S 53–59
34. Barraclough B (1972) Suicide prevention, recurrent affective disorder and lithium. Br J Psychiatry 121:391–392
35. Lauterbach E et al (2008) Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1‑year trial. Acta Sychiatr Scand 118:469–479
36. Müller-Oerlinghausen B, Lewitzka U (2016) The contributions of lithium and clozapine for the prophylaxis and treatment of suicidal behavior. In: Kaschka W, Rujescu D (Hrsg) Biological aspects of suicidal behavior. Karger, Basel, S 145–160
37. Pfennig A, Bauer M (2013) S3 guidelines on bipolar disorders are contemporary and important instruments for clinical practice. Nervenarzt 84:874–875
38. Lohse M, Müller-Oerlinghausen B (2015) Psychopharmaka. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungsreport 2015. Springer, Berlin Heidelberg New York
39. Werneke U et al (2012) A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiatr Scand 126(3):186–197
40. Baldessarini R, Tondo L, Hennen J (1999) Effects of lithium treatment and its discontinuation on suicidal behaviour in bipolar manic-depressive disorders. J Clin Psychiatry 60(Suppl 2):77–84
41. Meltzer H (2001) Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 932:44–58
42. Meltzer H (2002) Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatry Rep 4:279–283
43. Drake R, Ehrlich J (1985) Suicide attempts associated with akathisia. Am J Psychiatry 142:499–501
44. Meltzer H, Okayli G (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152:183–190
45. Walker A et al (1997) Mortality in current and former users of clozapine. Epidemiology 8:671–677
46. Meltzer H et al (2003) Clozapine tratment for suicidality in schizophrenia. Arch Gen Psychiatry 60:82–01